Clinical Scorecard: Transplantation of Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood in Patients with Decompensated Liver Cirrhosis

At a Glance

Key Highlights

• HUCB-MSC transplantation is a less invasive alternative to bone marrow stem cells with potential to improve liver function in DLC patients.
• Long-term efficacy and safety data on HUCB-MSC transplantation in liver cirrhosis are limited and require further study.
• Standard treatments for DLC include albumin supplementation, coagulation correction, liver protection, antiviral therapy, and management of complications.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of DLC based on medical history, clinical manifestations, blood tests, imaging, or liver biopsy.
• Hepatocellular carcinoma (HCC) diagnosis per Expert Consensus using ultrasonography, CT, or MRI.

Management

• Standard clinical treatments including albumin supplementation, coagulation correction, liver protection, antiviral treatment, and anti-infective therapy as needed.
• Consider HUCB-MSC transplantation as adjunct therapy after informed consent, noting current limitations in long-term safety data.

Monitoring & Follow-up

• Regular follow-up for survival outcomes and HCC occurrence using clinical records and imaging.
• Laboratory monitoring of liver function tests (ALT, AST, ALB, TBIL), coagulation parameters (PT, INR), renal function (creatinine), and platelet counts.

Risks

• Potential safety risks of stem cell transplantation include tumor development.
• Risks related to liver transplantation such as donor shortage, surgical injury, and immune rejection remain concerns.

Patient & Prescribing Data

Hospitalized patients with decompensated liver cirrhosis aged 18-75 years

HUCB-MSC transplantation was performed based on patient choice with informed consent; baseline characteristics were balanced using propensity score matching to compare outcomes with non-transplanted patients.

Clinical Best Practices

• Obtain informed consent prior to HUCB-MSC transplantation.
• Use propensity score matching or similar methods to minimize bias in observational studies evaluating stem cell therapies.
• Continue standard of care treatments for DLC alongside experimental therapies.
• Perform long-term follow-up to monitor survival and incidence of HCC post-transplantation.
• Exclude patients with concurrent serious diseases, prior liver cancer, or late-stage liver transplantation to ensure data integrity.

References

• Expert Consensus on Standardization of the Management of HCC in China